Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Thrombosis
•
Pediatric Hematology
•
Anticoagulation
•
Pediatric Oncology
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
Related Questions
How should clinicians approach the decision to use apixaban, or other DOACs, in pediatric patients with acute lymphoblastic leukemia or lymphoma who have additional risk factors for VTE, such as obesity or a family history of thrombosis, given the negative outcome of the PREVAPIX-ALL trial?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
How do you counsel an otherwise healthy patient on how soon they can go back to moderate exercise after a bilateral pulmonary embolism?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
What are your top takeaways from ISTH 2025?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
What are your top takeaways in Classical Hematology from ASH 2024?
